Evidence map›Paper›PMID 27679448›Full record

ReviewCurrent treatment options in neurology2016

Treatment Options for Urogenital Dysfunction in Parkinson's Disease.

Amit Batla, Natalie Tayim, Mahreen Pakzad, Jalesh N Panicker

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current treatment options in neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 35 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Urinary Tract Infection in Parkinson's Disease.Journal of Parkinson's disease · 2022
    Review
  8. Review
  9. Lower urinary tract dysfunction in Parkinsonian syndromes.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021
    Review
  10. Article
  11. Article
  12. Review
  13. Autonomic Dysfunction in Parkinson's Disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2020
    Review
  14. Review
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Amit BatlaUCL Institute of Neurology, Queen Square, 7 Queen Square, London, WC1N 3BG, UK. a.batla@ucl.ac.uk.
Natalie TayimDepartment of Uro-Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
Mahreen PakzadDepartment of Uro-Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.
Jalesh N PanickerDepartment of Uro-Neurology, The National Hospital for Neurology and Neurosurgery and UCL Institute of Neurology, Queen Square, London, UK.
National Hospital for Neurology and Neurosurgery · GBUniversity College London · GB

Funding

Parkinson's UK K-1303
6 · The paper itself

Abstract

opinion statementUrogenital dysfunction is commonly reported in Parkinson's disease (PD), and history taking and a bladder diary form the cornerstone of evaluation. The assessment of lower urinary tract (LUT) symptoms include urinalysis, ultrasonography, and urodynamic studies and help to evaluate concomitant urological pathologies such as benign prostate enlargement. Antimuscarinic medications are the first line treatment for overactive bladder (OAB) symptoms and solifenacin has been specifically studied in PD. Antimuscarininc drugs may exacerbate PD-related constipation and xerostomia, and caution is advised when using these medications in individuals where cognitive impairment is suspected. Desmopressin is effective for the management of nocturnal polyuria which has been reported to be common in PD. Intradetrusor injections of botulinum toxin have been shown to be effective for detrusor overactivity, however, are associated with the risk of urinary retention. Neuromodulation is a promising, minimally invasive treatment for PD-related OAB symptoms. Erectile dysfunction is commonly reported and first line treatments include phosphodiesterase-5 inhibitors. A patient-tailored approach is required for the optimal management of urogenital dysfunction in PD.

Indexed as

Bladder diary Parkinson’s diseaseDetrusor overactivityErectile dysfunctionIncontinenceLower urinary tractUrodynamics

Identifiers

PMID27679448
PMCPMC5039223
OpenAlexW2524392074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.